Get the Stockscreener App
7.1944
0.69%
-0.0356
CorMedix Inc stock is traded at $7.1944, with a volume of 231.59K.
It is down -0.69% in the last 24 hours and up +9.79% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$7.23
Open:
$7.26
24h Volume:
231.59K
Relative Volume:
0.13
Market Cap:
$567.98M
Revenue:
$311.71M
Net Income/Loss:
$163.05M
P/E Ratio:
3.6271
EPS:
1.9835
Net Cash Flow:
$172.79M
1W Performance:
-2.45%
1M Performance:
+9.79%
6M Performance:
-28.77%
1Y Performance:
-4.52%
1-Day Range:
$7.14
$7.34
1-Week Range:
$7.14
$7.48
52-Week Range:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.185 | 571.53M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
439.81 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.20 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
835.00 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.33 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
321.26 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
How (CRMD) Movements Inform Risk Allocation Models - Stock Traders Daily
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Do options traders know something about CorMedix stock we don't? - MSN
Airway Therapeutics Appoints Biopharma Leader Joe Todisco to Board of Directors - Bolsamania
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets - Yahoo Finance
CorMedix: A Shrinking Core And No Proven Second Engine (NASDAQ:CRMD) - Seeking Alpha
CorMedix to Participate in Needham Virtual Healthcare Conference - Sahm
CRMD Forecast, Price Target & Analyst Ratings | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
RSI Check: What makes CorMedix Inc stock attractive todayWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Trading Systems Reacting to (CRMD) Volatility - Stock Traders Daily
CorMedix Inc. (CRMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade) (NASDAQ:CRMD) - Seeking Alpha
Quarterly Risk: What makes CorMedix Inc stock attractive today2026 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
CRMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast? - MSN
CorMedix Q4 2025 Earnings Call Transcript - MarketBeat
Market Trends: Why is CorMedix Inc stock going downQuarterly Investment Review & Community Consensus Trade Alerts - baoquankhu1.vn
CorMedix soars on increased Q2 sales guidance - MSN
Aug Update: Why is CorMedix Inc stock going downQuarterly Risk Review & Long-Term Growth Stock Strategies - baoquankhu1.vn
Vanguard disaggregates holdings; reports 0% in CorMedix (CRMD) - Stock Titan
Do Options Traders Know Something About CorMedix Stock We Don't? - Zacks Investment Research
How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset - Yahoo Finance
How Cormedix Inc. (CRMD) Affects Rotational Strategy Timing - Stock Traders Daily
Levels Update: Can CorMedix Inc outperform under higher oil pricesWeekly Stock Analysis & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines? - simplywall.st
US Market Recap: What is the target price for CorMedix Inc stock2026 Stock Rankings & Daily Profit Focused Stock Screening - baoquankhu1.vn
Street Watch: Is CorMedix Inc a stock for growth or value investors2026 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Shorts: What makes CorMedix Inc stock attractive todayWeekly Trend Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Why did CRMD stock tumble over 11% today? - MSN
CorMedix at Citizens Life Sciences: Strategic Expansion and Growth By Investing.com - Investing.com Canada
CRMD: REZZAYO and DefenCath drive growth, with Melinta boosting revenue and new markets targeted - TradingView
CorMedix at Leerink Conference: Strategic Evolution and Market Potential By Investing.com - Investing.com Nigeria
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead - TipRanks
CorMedix at Leerink Conference: Strategic Evolution and Market Potential - Investing.com
CRMD: Diversified specialty pharma advancing REZZAYO and DefenCath, with strong growth catalysts ahead - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com Nigeria
What is CorMedix Inc.’s book value per shareMarket Weekly Review & Fast Moving Stock Trade Plans - baoquankhu1.vn
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? - MSN
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit SwingWhat's Changed - simplywall.st
CorMedix Q4 2025 earnings preview - MSN
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix (CRMD) lags Q4 earnings estimates - MSN
CorMedix Therapeutics 2026: Portfolio Expansion, Financial Highlights, DefenCath Launch & Growth Pipeline in Specialty Pharma 1234567 - Minichart
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - MSN
CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio - MSN
Leerink cuts CorMedix stock price target on expense adjustments - Investing.com India
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):